Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies

Transplant Infectious Disease

Volumn 6, Issue 2, 2004, Pages 63-68

  Ozaki, K S ^a,b   Pestana, J O M ^a,b   Granato, C F H ^a   Pacheco Silva, Alvaro ^a,b   Camargo, L F A ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

Author keywords

Antigenemia; Antilymphocyte antibody; Cytomegalovirus; Renal transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; FINGOLIMOD; GANCICLOVIR; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ANTIGEN DETECTION; ARTICLE; CADAVER DONOR; CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY;

ADULT; ANTILYMPHOCYTE SERUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHOPROTEINS; TIME FACTORS; VIRAL MATRIX PROTEINS;

EID: 9144229491     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2004.00054.x     Document Type: Article

References (35)

1. BRENNAN DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001: 12: 848-855.
2. RUBIN RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990: 12: S754-S766.
3. SAGEDAL S, NORDAL KN, HARTMANN A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000: 70: 1166-1174.
4. TOLKOFF-RUBIN NE, RUBIN RH.The impact of cytomegalovirus infection on graft function and patient outcome. Graft 1999: 2: S101-S103.
5. BRENNAN DC. Cytomegalovirus: implications, diagnosis and treatment. Graft 1999: 2: 74-77.
6. HIBBERD PL, TOLKOFF-RUBIN NE, COSIMI AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992: 53: 68-72.
7. JAGOSE JT, BAILEY RR, LYNN KL, et al. OKT3 for the treatment of steroid-resistant acute renal allograft rejection. Nephron 1997: 77: 298-303.
8. OH CS, STRATTA RJ, FOX BC, et al. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 1988: 45: 68-73.
9. BAILEY TC, POWDERLY WG, STORCH GA, et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993: 21: 196-201.
10. GÓMEZ E, OÑA M, AGUADO S, et al. Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3. Nephron 1996: 74: 367-372.
11. COUCHOUD C, CUCHERAT M, HAUGH M, et al. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 1998: 65: 641-647.
12. HIBBERD PL, TOLKOFF-RUBIN NE, CONTI D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995: 123: 18-26.
13. EGAN JJ, LOMAX J, BARBER L, et al. Preemptive treatment for the prevention of cytomegalovirus disease. Transplantation 1998: 15: 747-752.
14. KUSNE S, GROSSI P, IRISH W, et al. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999: 68: 1125-1131.
15. CAMARGO LFA, UIP DE, SIMPSON AAG, et al. Comparison between antigenemia and a quantitative-competitive polymerase chain reaction for the diagnosis of cytomegalovirus infection after heart transplantation. Transplantation 2001: 71: 412-417.
16. THE TH, VAN DER BIJ W, VAN DEN BERG AP, et al. Cytomegalovirus antigenemia. Rev Infect Dis 1990: 12: S737-S743.
17. SHIELD CF III, JACOBS RJ, WYANT S, DAS A. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 1996: 27: 855-864.
18. SHIELD CF, EDWARDs EB, DAVIES DB, DAILY OP. Antilymphocyte induction therapy in cadaver renal transplantation. Transplantation 1997: 63: 1257-1263.
19. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313: 337-342.
20. MONACO AP. A new look at polyclonal antilymphocyte antibodies in clinical transplantation. Graft 2000: 15: S2-S5.
21. FLECHNER SM, GOLDFARB DA, FAIRCHILD R, et al. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants. Transplantation 2000: 69: 2374-2381.
22. LAUGE H, MÜLLER TF, EBEL H, et al. Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function. Tranpl Int 1999: 12: 2-9.
23. LAUTENSCHLAGER I, SOOTS A, KROGERUS L, et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 1997: 64: 391-398.
24. HELANTERA I, KOSKINEN P, TORNROTH T, LOGINOV R, GRONHAGEN-RISKA C, LAUTENSCHLAGER I. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation 2003: 75: 1858-1864.
25. LOWANCE D, NEUMAYER HH, LEGENDRE CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International valacyclovir cytomegalovirus prophylaxis transplantation study group. N Engl J Med 1999: 340: 1462-1470.
26. RUBIN RH, KEMMERLY SA, CONTI D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000: 2: 112-117.
27. VALANTINE HA, GAO SZ, MENON SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999: 100: 61-66.
28. ROBERTS TC, BRENNAN DC, BULLER RS, et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998: 178: 626-635.
29. VAN DER BIJ W, VAN SON WJ, VAN DEN BERG APM, TEGZESS AM, TORENSMA R, THE TH. Cytomegalovirus (CMV) antigenemia: rapid diagnosis and relationship with CMV-associated clinical syndromes in renal allograft recipients. Transplant Proc 1989: 21: 2061-2064.
30. ERICE A, CHOU S, BIRON KK, et al. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989: 320: 289-293.
31. ROSEN HR, BENNER KG, FLORA KD, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997: 63: 476-478.
32. TANABE K, TOKUMOTO T, ISHIKAWA N, et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997: 64: 1721-1725.
33. DURLIK M, SIENNICKA J, LITWI'NSKA B, et al. Comparison of antigenemia (pp65) assay and polymerase chain reaction in diagnosis of cytomegalovirus infection in renal transplant recipient treated with ATG. Tranplant Proc 2000: 32: 1350-1352.
34. AKPOSSO K, RONDEAU E, HAYMANN JP, et al. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation 1997: 63: 974-976.
35. VAN DER BIJ W, SPEICH R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001: 33 (Suppl 1): S32-S37.